Acumen Pharmaceuticals, Inc.

ABOS

Explore Our Financial Data > Companies > Acumen Pharmaceuticals, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ABOS
CIK	0001576885
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	427 PARK ST., CHARLOTTESVILLE, VA, 22902
Website	acumenpharm.com
Phone	925-368-8508
CEO	Daniel J. OConnell
Employees	20

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$0.00
Pre-Tax Income	$-121.34 million
Net Income	$-121.34 million
Net Income to Common	$-121.34 million
EPS	$-2.00

View All

Balance Sheet

Cash	$53.99 million
Assets	$122.83 million
Liabilities	$52.40 million
Common Equity	$70.43 million
Liabilities & Equity	$122.83 million

View All

Cash Flow Statement

Net Income	$-121.34 million
Cash From Operating Activities	$-115.54 million
Cash From Investing Activities	$133.93 million
Cash From Financing Activities	$-34,000.00
Change in Cash	$18.36 million

View All

Calculations

NOPAT	$-86.68 million
EBITDA	$-125.18 million
Price to Earnings	N/A
Price to Book	$2.64
ROE	N/A

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter financial results on Tuesday, May 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financi

Article Link

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Article Link

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.

Article Link

Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Moby summary of Acumen Pharmaceuticals, Inc.'s Q4 2025 earnings call

Article Link

Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...

Acumen Pharmaceuticals Inc (ABOS) reports significant clinical progress and strategic partnerships, despite increased R&D expenses and a net loss for 2025.

Article Link